Werewolf Therapeutics, Inc. (HOWL): restructuring charge — Werewolf Therapeutics cuts 64% of workforce; CFO and CMO depart; appoints new principal financial officer

Werewolf Therapeutics, Inc.

Reduction in force affecting 64% of workforce; expected completion by Feb 13, 2026.
Estimated one-time charge of ~$4.1 million in Q1 2026 for severance and benefits.
CFO Timothy Trost and CMO Randi Isaacs resign effective Feb 13, 2026; enter 6-month consulting agreements at $250/hour.
Michael Urban named principal financial and accounting officer, effective Feb 13, 2026.
Company evaluating strategic alternatives for WTX-124 and WTX-330 programs; no assurance of transaction.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Werewolf Therapeutics, Inc. announced a restructuring with charges of approximately $4.1 million (64% of the Company’s workforce).

Type: restructuring
Charge: approximately $4.1 million
Headcount: 64% of the Company’s workforce

Exact text from the filing

estimates that it will record a one-time charge in the first quarter of 2026 related to employee separation benefits, including severance and related benefits, of approximately $4.1 million, all of which is anticipated to result in cash expenditures to be incurred in the first quarter of 2026. The Company may also incur additional costs not currently contemplated

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-051455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.